1. Home
  2. RBBN vs ALT Comparison

RBBN vs ALT Comparison

Compare RBBN & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ribbon Communications Inc.

RBBN

Ribbon Communications Inc.

HOLD

Current Price

$2.45

Market Cap

493.4M

Sector

Technology

ML Signal

HOLD

Logo Altimmune Inc.

ALT

Altimmune Inc.

HOLD

Current Price

$3.02

Market Cap

421.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RBBN
ALT
Founded
1997
1997
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
493.4M
421.5M
IPO Year
2017
2005

Fundamental Metrics

Financial Performance
Metric
RBBN
ALT
Price
$2.45
$3.02
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$4.67
$17.67
AVG Volume (30 Days)
1.1M
3.3M
Earning Date
04-28-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
170.97
25.37
EPS
N/A
N/A
Revenue
N/A
$41,000.00
Revenue This Year
$1.97
N/A
Revenue Next Year
$6.69
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
105.00
52 Week Low
$1.83
$2.56
52 Week High
$4.29
$7.73

Technical Indicators

Market Signals
Indicator
RBBN
ALT
Relative Strength Index (RSI) 37.50 59.65
Support Level $2.36 $2.87
Resistance Level $2.46 $3.20
Average True Range (ATR) 0.15 0.13
MACD -0.06 0.04
Stochastic Oscillator 2.84 94.73

Price Performance

Historical Comparison
RBBN
ALT

About RBBN Ribbon Communications Inc.

Ribbon Communications Inc provides communications technology to service providers and enterprises, offering software and high-performance hardware products, network solutions, and services for secure data and voice communications, as well as high-bandwidth networking for residential and enterprise customers across industries such as finance, education, government, utilities, and transportation. It operates through two segments: Cloud and Edge, which generate maximum revenue and deliver software-centric, cloud-native solutions for VoIP, VoLTE, VoNR, and unified communications, and IP Optical Networks, which support growing telecommunications traffic from 5G, distributed cloud computing, and other applications. The Company generates the majority of its revenue from the United States.

About ALT Altimmune Inc.

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: